SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

Vaccines

Jocelyn Ollier¹  Thierry Guillaume¹  Marie C. Béné¹  Patrice Chevallier¹  Audrey Grain¹  Béatrice Clémenceau¹  Henri Vié¹  Maxime Jullien²  Pierre Peterlin²  Alice Garnier²  Amandine Le Bourgeois²  Marianne Coste-Burel³ 

[1] CHU Nantes, CRCINA, INSERM, CNRS, Université de Nantes, F-44000 Nantes, France;Hematology Department, Nantes University Hospital, Nantes University, F-44000 Nantes, France;Virology Department, Nantes University Hospital, Nantes University, F-44000 Nantes, France;

关键词: COVID 19;    vaccine;    BNT162b2;    SARS-CoV-2 mRNA;    allogeneic hematopoietic stem cell transplantation;    cellular immunity;   

DOI  :  10.3390/vaccines10030448

来源: DOAJ

【 摘 要 】

Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2 vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell transplantation (Allo-HSCT), especially within the first post-transplant years where immunosuppression is more profound and harmful. Methods: SARS-CoV-2 Spike protein-specific T-cell responses were explored after two doses of BNT162b2 mRNA vaccine in 45 Allo-HSCT recipients with a median time from transplant of less than 2 years by using INF-γ ELISPOT assay and flow-cytometry enumeration of CD4⁺ and CD8⁺ T lymphocytes with intracellular cytokine production of IFN-γ and TNF-α. Results: A strong TNF-α⁺ response from SARS-CoV-2-specific CD4⁺ T-cells was detected in a majority of humoral responders (89%) as well as in a consistent population of non-humoral responders (40%). Conclusions: T-cells are likely to participate in protection against COVID-19 viral infection, even in the absence of detectable antibody response, especially in the first years post-transplant in Allo-HSCT recipients.

【 授权许可】

Unknown